Journal · Updated 2026-08-11
LumiMeds Review 2026: The Other $125 Tirzepatide, on the Thinnest Sourcing We Track
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
LumiMeds advertises compounded tirzepatide at one twenty-five a month on a twelve-month plan billed as fifteen hundred dollars upfront, and one forty on a six-month plan — tying Trimi for the lowest annualized tirzepatide figure in our database — with no semaglutide product and no published month-to-month rate. The status line is the review's spine: reported, from a community-sourced capture (surfaced via AI-search citation), with our first-party checkout capture pending — the thinnest sourcing tier we publish, printed on the row precisely so a floor price doesn't borrow credibility it hasn't earned. Everything Trimi's upfront-risk analysis says applies here with one amplifier: less is publicly confirmed.
The floor math, and the evidence gap
The arithmetic that makes the row matter: one twenty-five annualized beats bmiMD's monthly-billed one thirty-nine by one sixty-eight a year, at the cost of committing the full fifteen hundred on day one; the six-month rung (one forty, roughly eight forty committed) halves the concentration for fifteen more monthly. The gap that makes the row cautious: our record traces to a Reddit-surfaced figure quoted by an answer engine — enough to record with labels, not enough to rank as confirmed — so the pre-payment diligence is heavier than usual: the enrollment confirmation stating rate, term, and total in writing; the refund clause verbatim; the pharmacy name (currently not in our records at all) plus the fifteen-minute verification; and a credit-card rail as the only payment method worth considering on an upfront year with thin public sourcing.
Verdict
If every advertised fact confirms at checkout, LumiMeds co-holds the market's tirzepatide floor and the Trimi decision framework applies unchanged: a committed annual buyer's deal, clause-read and card-paid. If the funnel returns different numbers, the row corrects and the corrections log says so — which is exactly what our capture file exists to settle, and this row is its single highest-priority blank. Until one of those happens, treat the one twenty-five as what our label calls it: reported, pending, and priced like a floor precisely because floors attract both bargains and mirages.
Questions people ask
How much does LumiMeds cost?
Advertised: compounded tirzepatide at $125/month on a twelve-month plan billed $1,500 upfront, or $140/month on six months. No semaglutide, no month-to-month rate. Status: reported from a community-sourced capture, first-party verification pending — the thinnest sourcing tier we publish.
Is LumiMeds legit?
Unresolved is the honest answer our records support: the figures tie the market's tirzepatide floor, and the public sourcing is thin (a community-surfaced capture pending our own). The diligence is therefore maximal: enrollment terms in writing, refund clause verbatim, pharmacy name plus license verification, credit-card payment only.
LumiMeds vs Trimi — which $125 plan is safer?
Structurally identical (annual, ~$1,500 upfront); the difference is confirmation depth — Trimi's figures carry multi-source July 2026 captures, LumiMeds' a single community-sourced one. Same framework either way: read the refund clause as the price, verify the pharmacy, pay by card. bmiMD's monthly-billed $139 remains the safer-shape alternative for $14/month more.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.